Literature DB >> 19477134

QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum.

Fang Zheng1, Matthew J McConnell, Chang-Guo Zhan, Linda P Dwoskin, Peter A Crooks.   

Abstract

Maximal inhibition (I(max)) of the agonist effect is an important pharmacological property of inhibitors that interact with multiple receptor subtypes that are activated by the same agonist and which elicit the same functional response. This report represents the first QSAR study on a set of 66 mono- and bis-quaternary ammonium salts that act as antagonists at neuronal nicotinic acetylcholine receptors mediating nicotine-evoked dopamine release, conducted using multi-linear regression (MLR) and neural network (NN) analysis with the maximal inhibition (I(max)) values of the antagonists as target values. The statistical results for the generated MLR model were: r(2)=0.89, rmsd=9.01, q(2)=0.83 and loormsd=11.1; the statistical results for the generated NN model were: r(2)=0.89, rmsd=8.98, q(2)=0.83 and loormsd=11.2. The maximal inhibition values of the compounds exhibited a good correlation with the predictions made by the QSAR models developed, which provide a basis for rationalizing selection of compounds for synthesis in the discovery of effective and selective second generation inhibitors of nAChRs mediating nicotine-evoked dopamine release.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19477134      PMCID: PMC3914672          DOI: 10.1016/j.bmc.2009.05.010

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  37 in total

Review 1.  Competitive neuronal nicotinic receptor antagonists: a new direction for drug discovery.

Authors:  L P Dwoskin; P A Crooks
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

2.  Development of subtype-selective ligands as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release.

Authors:  Peter A Crooks; Joshua T Ayers; Rui Xu; Sangeetha P Sumithran; Vladimir P Grinevich; Lincoln H Wilkins; A Gabriela Deaciuc; David D Allen; Linda P Dwoskin
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

3.  Modeling differential binding of alpha4beta2 nicotinic acetylcholine receptor with agonists and antagonists.

Authors:  Xiaoqin Huang; Fang Zheng; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2008-12-10       Impact factor: 15.419

4.  Involvement of the alpha3 subunit in central nicotinic binding populations.

Authors:  Paul Whiteaker; Cyrus G Peterson; Wei Xu; J Michael McIntosh; Richard Paylor; Arthur L Beaudet; Allan C Collins; Michael J Marks
Journal:  J Neurosci       Date:  2002-04-01       Impact factor: 6.167

5.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonist: inhibition of S(-)-nicotine-evoked [(3)H]dopamine overflow from superfused rat striatal slices.

Authors:  Lincoln H Wilkins; Aaron Haubner; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2002-06       Impact factor: 4.030

6.  Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  J Enzyme Inhib Med Chem       Date:  2009-02       Impact factor: 5.051

7.  Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents.

Authors:  Linda P Dwoskin; Sangeetha P Sumithran; Jun Zhu; A Gabriela Deaciuc; Joshua T Ayers; Peter A Crooks
Journal:  Bioorg Med Chem Lett       Date:  2004-04-19       Impact factor: 2.823

8.  N-n-alkylnicotinium analogs, a novel class of nicotinic receptor antagonists: interaction with alpha4beta2* and alpha7* neuronal nicotinic receptors.

Authors:  Lincoln H Wilkins; Vladimir P Grinevich; Joshua T Ayers; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

9.  Analogs of alpha-conotoxin MII are selective for alpha6-containing nicotinic acetylcholine receptors.

Authors:  J Michael McIntosh; Layla Azam; Sarah Staheli; Cheryl Dowell; Jon M Lindstrom; Alexander Kuryatov; James E Garrett; Michael J Marks; Paul Whiteaker
Journal:  Mol Pharmacol       Date:  2004-04       Impact factor: 4.436

10.  Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice.

Authors:  Nicolas Champtiaux; Zhi-Yan Han; Alain Bessis; Francesco Mattia Rossi; Michele Zoli; Lisa Marubio; J Michael McIntosh; Jean-Pierre Changeux
Journal:  J Neurosci       Date:  2002-02-15       Impact factor: 6.167

View more
  4 in total

Review 1.  Nicotinic receptor antagonists as treatments for nicotine abuse.

Authors:  Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  Adv Pharmacol       Date:  2014

2.  Improved Prediction of Blood-Brain Barrier Permeability Through Machine Learning with Combined Use of Molecular Property-Based Descriptors and Fingerprints.

Authors:  Yaxia Yuan; Fang Zheng; Chang-Guo Zhan
Journal:  AAPS J       Date:  2018-03-21       Impact factor: 4.009

3.  Modeling in vitro inhibition of butyrylcholinesterase using molecular docking, multi-linear regression and artificial neural network approaches.

Authors:  Fang Zheng; Max Zhan; Xiaoqin Huang; Mohamed Diwan M Abdul Hameed; Chang-Guo Zhan
Journal:  Bioorg Med Chem       Date:  2013-11-08       Impact factor: 3.641

4.  Wide-Antimicrobial Spectrum of Picolinium Salts.

Authors:  Sarka Salajkova; Marketa Benkova; Jan Marek; Radek Sleha; Lukas Prchal; David Malinak; Rafael Dolezal; Kristina Sepčić; Nina Gunde-Cimerman; Kamil Kuca; Ondrej Soukup
Journal:  Molecules       Date:  2020-05-11       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.